
What is claimed is:

1. A compound of Formula (I):



(I)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

$\overline{---}$ designates a single or double bond;

x and y can be both a single bond; when x is a double bond, then y is a single bond and R^4 and R^{16} are absent; when y is a double bond, then x is a single bond and R^5 and R^{16} are absent;

R^1 is independently selected from the group consisting of: -CONH(C_{4-18} alkyl), -CONHC_{2-8} haloalkyl, -CONH$(CH_2)_{1-8}$Ph, -CONHCH_2COC_{2-8} alkyl, -$(CH_2)_m$-(C_{3-10} carbocycle substituted with 0-2 R^b and 0-2 R^g), -$(CH_2)_m$-(5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g), and a C_{1-12} hydrocarbon chain substituted with 0-3 R^a; wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;

R^2 is independently selected from the group consisting of: C_{1-4} alkyl, C_{3-4} cycloalkyl, and C_{1-4} haloalkyl;

R^3 is independently selected from the group consisting of: H, F, Cl, C_{1-4} alkyl and CN;

R^4 and R^5 are independently selected from the group consisting of: H, F, Cl, and C_{1-4} alkyl;

when x is a single bond, R^3 and R^4 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R^6 is independently selected from the group consisting of: H, halo, C_{1-4} alkyl, NO_2, R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, NH_2, $-CONH(C_{1-6}$ alkyl), $-NHCOX_1SO_2R^j$, $-NHCOCH_2PO(OEt)_2$, $-NHCOCOR^j$, $-NHCOCH(OH)R^j$, $-NHCOCH_2COR^j$, $-NHCONHR^j$, and $-OCONR^fR^j$;

X is independently selected from the group consisting of: O, S, NH, CONH, and NHCO;

X_1 is independently C_{1-4} hydrocarbon chain optionally substituted with C_{1-4} alkyl or C_{3-4} cycloalkyl;

when y is a single bond, R^5 and R^6 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R^{11}, R^{12}, R^{13}, R^{14} and R^{15} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-2 R^i, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $-(CH_2)_m-C_{3-6}$ cycloalkyl, CN, NR^fR^j, OR^j, SR^j, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S;

alternatively, R^{11} and R^{12}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

R^{16} is independently selected from the group consisting of: H and C_{1-4} alkyl;

R^a is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $N(C_{1-4}$ alkyl$)_2$, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, and $-(CH_2)_n-(CH_2O)_m-(CH_2)_nR^f$;

R^b is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-10} alkyl, C_{1-10} alkoxy, C_{1-10} haloalkyl, C_{1-10} haloalkoxy, C_{1-10} alkylthio,

C_{1-10} haloalkylthio, $N(C_{1-4}$ alkyl$)_2$, $-CONH(CH_2)_{4-20}H$, $-O(CH_2)_sO(C_{1-6}$ alkyl), R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, and $-(CH_2)_n-(CH_2O)_m-(CH_2)_nR^f$;

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, C_{3-6} cycloalkenyl substituted with 0-2 R^d, $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S; wherein said heterocycle is substituted with 0-2 R^d;

R^d is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, NO_2, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl, OBn and phenyl substituted with 0-2 R^h;

R^e is, at each occurrence, independently selected from the group consisting of: H, C_{1-8} alkyl, C_{1-8} haloalkyl, benzyl optionally substituted with C_{1-4} alkoxy, $CO(C_{1-4}$ alkyl) and COBn;

R^f is, at each occurrence, independently selected from the group consisting of: H and

C_{1-4} alkyl;

R^g, R^h and R^i are, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

R^j is, at each occurrence, independently selected from the group consisting of: C_{1-4} alkyl,

C_{3-4} cycloalkyl and phenyl;


n, at each occurrence, is independently 0 or 1;

m, at each occurrence, is independently 0, 1, 2, 3, or 4


s, at each occurrence, is independently 1, 2, or 3; and

t, at each occurrence, is independently 0 or 1;

provided that the following compound is excluded:



2. A compound according to claim 1, wherein:

R^1 is independently selected from the group consisting of: -$CONHC_{4-18}$ alkyl, -$CONH(CH_2)_{1-8}$ Ph, C_{1-12} alkyl substituted with 0-2 R^a, C_{1-12} alkenyl substituted with 0-2 R^a, C_{1-12} alkynyl substituted with 0-2 R^a, -$(CH_2)_m$-(phenyl substituted with 0-1 R^b and 0-2 R^g), -$(CH_2)_m$-(C_{3-6} cycloalkyl substituted with 0-1 R^b), and -$(CH_2)_m$-(5- to 6-membered heteroaryl substituted with 0-1 R^b and 0-2 R^g), wherein said heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and .


3. A compound according to claim 1 or claim 2, wherein:

R^{11} and R^{15} are independently selected from the group consisting of: H, C_{1-4} alkyl and halo;

R^{12} and R^{14} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy; and

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 R^i, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, -$(CH_2)_m$-C_{3-4} cycloalkyl, CN, NR^fR^j, SR^j, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S.


4. A compound according to any one of claims 1 to 3, wherein the compound is of Formula (II):



(II)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of claims 1 to 4, wherein:

R^1 is independently selected from the group consisting of: C_{1-6} alkyl, C_{3-6} cycloalkyl, $-CONHC_{4-18}$ alkyl, $-CONHC_{2-8}$ haloalkyl, $-CONH(CH_2)_{1-8}$ Ph, $-(CH_2)_m$-(phenyl substituted with 1 R^b and 0-2 R^g), and a 5- to 6-membered heteroaryl substituted with 0-1 R^b and 0-2 R^g, wherein said heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and  ;

R^2 is independently selected from the group consisting of: C_{1-4} alkyl and C_{1-4} haloalkyl;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from the group consisting of: NH_2, $-CONH(C_{1-6}$ alkyl), R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, $-NHCO(CH_2)SO_2(C_{1-4}$ alkyl), $-NHCOCH_2PO(OEt)_2$, $-NHCOCO(C_{1-4}$ alkyl), $-NHCOCH(OH)(C_{1-4}$ alkyl), $-NHCOCH_2CO(C_{1-4}$ alkyl), $-NHCONH(C_{1-4}$ alkyl), and $-OCONH(C_{1-4}$ alkyl);

R^{11} and R^{15} are independently selected from the group consisting of: H, C_{1-4} alkyl and halo;

R^{12} and R^{14} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $-(CH_2)_m-C_{3-4}$ cycloalkyl, CN, $N(C_{1-4}$ alkyl$)_2$, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), pyrazolyl, and morpholinyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

R^b is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} haloalkyl, C_{1-10} haloalkoxy, $-O(CH_2)_sO(C_{1-6}$

alkyl), $N(C_{1-4}$ alkyl$)_2$, $-CONH(CH_2)_{6-20}H$, $-(CH_2)_m(C_{3-6}$ cycloalkyl), $-(CH_2)_m(C_{4-6}$ cycloalkenyl), $-O(CH_2)_m(C_{3-6}$ cycloalkyl), 4-C_{1-4} alkoxy-Ph, $-O(CH_2)_m$Ph, morpholinyl, pyridyl, 2-C_{1-4} alkoxy-pyridin-5-yl, pyrimidinyl, pyrazinyl, and -O-pyrimidinyl;


R^g is, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

m, at each occurrence, is independently 0, 1, 2 or 3; and

s, at each occurrence, is independently 1, 2, or 3.

6. A compound according to any one of claims 1 to 5, wherein:

R^1 is independently selected from the group consisting of: C_{1-6} alkyl,



$-CONHC_{4-18}$ alkyl, $-CONH(CH_2)_{1-8}$Ph, and ;

R^6 is independently selected from the group consisting of: NH_2, $-CONH(C_{1-6}$ alkyl), $-NHCOCH_2PO(OEt)_2$, $-NHCO(CH_2)SO_2(C_{1-4}$ alkyl), R^c, OR^c, $-CONHR^c$, and $-NHCOR^c$;

R^{12} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $-(CH_2)_m$-C_{3-4} cycloalkyl, CN, $N(C_{1-4}$ alkyl$)_2$, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), pyrazolyl, and morpholinyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is independently selected from the group consisting of: H and C_{1-4} alkoxy;

R^b is, at each occurrence, independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-10} haloalkoxy, $-O(CH_2)_sO(C_{1-6}$ alkyl), $-CONH(CH_2)_{6-20}H$, $-(CH_2)_m(C_{3-6}$ cycloalkyl), $-(CH_2)_m(C_{4-6}$ cycloalkenyl),

-O$(CH_2)_m$(C_{3-6} cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C_{1-4} alkoxy-pyridin-5-yl, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidinyl; and

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, -$(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d.

7. A compound according to any one of claims 1-6, wherein:

R^2 is independently selected from the group consisting of: CF_3 and Me;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from the group consisting of: NH_2, -CONHMe, OPh, -CONH(cyclopropyl), -CONH(cyclobutyl), -CONH(cyclopentyl), -CONH(cyclohexyl), -CONHPh, -CONH(4-F-Ph), -CONH(2-Cl-Ph), -CONH(4-Cl-Ph), -CONH(4-Me-Ph), -CONH(4-OH-Ph), -CONH(3-OMe-Ph), -CONH(4-OMe-Ph), -CONH(4-CF_3-Ph), -CONH(4-OCF_3-Ph), -CONH(1-Me-pyrazol-3-yl), -CONH(4-(1*H*-tetrazol-2-yl)-Ph), -CONH(4-(2*H*-tetrazol-5-yl)-Ph), -CONH(3-F-4-Me-Ph), -CONH(3-F-4-OMe-Ph), -CONH$(CH_2)_2$Ph, -CONH(5-OMe-pyrid-2-yl), -CONH(6-OMe-pyrid-3-yl), -CONH(5-OMe-pyrazin-2-yl), -CONH(6-OMe-pyridazin-3-yl), -NHCO$(CH_2)SO_2$Me, -NHCOPh, -NHCO(2-Me-Ph), -NHCO(3-Me-Ph), -NHCO(4-Me-Ph), -NHCO(2-Cl-Ph), -NHCO(3-Cl-Ph), -NHCO(2-Cl-4-F-Ph), -NHCO(2-Cl-5-F-Ph), -NHCO(isoxazol-5-yl), -NHCO(3-Me-isoxazol-5-yl), -NHCO(4-Me-isoxazol-5-yl), -NHCO(3-OMe-isoxazol-5-yl), -NHCO(3-Br-isoxazol-5-yl), -NHCO(3-(2-Cl-Ph)-isoxazol-5-yl), -NHCO(3-(3-F-Ph)-isoxazol-5-yl), -NHCO(3-OBn-isoxazol-5-yl), 1*H*-imidazol-1-yl, -NHCO(5-Me-1,3,4-oxadiazol-2-yl), -NHCO(1-Me-1,2,3-triazol-4-yl), -NHCO(6-OMe-pyrid-3-yl), -NHCO(6-Cl-pyridazin-3-yl), 5-CF_3-1,3,4-oxadiazol-2-yl, 1*H*-tetrazol-1-yl, 1*H*-tetrazol-3-yl, and 2*H*-tetrazol-5-yl;

R^{11} and R^{15} are independently selected from the group consisting of: H, Me, F, and Cl;

R^{12} is independently selected from the group consisting of: H, F, Cl, Me and OMe;

R^{13} is independently selected from the group consisting of: H, F, Cl, Br, Me, OMe, OEt, CH_2OMe, CF_3, CH_2CF_3, $OCHF_2$, OCF_3, CN, $N(Me)_2$, cyclopropyl and cyclopropylmethyl;


alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is H;

R^b is, at each occurrence, independently selected from the group consisting of: n-pentyl, methoxy, n-butoxy, i-butoxy, i-pentoxy, $-O(CH_2)_{1-6}CF_3$, $-O(CH_2)_{1-4}CF_2CF_3$, $-CONH(CH_2)_{6-20}H$, cyclopropyl, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, $-O(CH_2)_2$(cyclopentyl), phenoxy, benzoxy, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidin-2-yl; and

R^g is F.

8. A compound according to Claim 4 or Claim 5, wherein:

R^1 is 

;

R^2 is independently selected from CF_3 and CH_3;

R^6 is independently selected from: R^c, $-CONHR^c$, $-NHCOR^c$, and $-NHCOCH_2SO_2(C_{1-4}$ alkyl);

R^b is independently selected from: $-O(CH_2)_{1-6}CF_3$, $-O(CH_2)_{1-4}CF_2CF_3$, $-CONH(CH_2)_{6-20}H$, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, $-O(CH_2)_2$(cyclopentyl), phenoxy, benzoxy, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidin-2-yl;

R^c is, at each occurrence, independently selected from the group consisting of: $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d; and

R^d is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl and OBn.

9. A compound according to any of claims 1 to 6 or 8, wherein:

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, CN or C_{3-4} cycloalkyl.

10. A compound according to any one of claims 1-5, 8 or 9 wherein:

R^1 is independently .

11. A compound according to any one of claims 1-10, wherein:

R^b is independently selected from: $-O(CH_2)_{1-6}CF_3$, and $-O(CH_2)_{1-4}CF_2CF_3$.

12. A compound according to any one of claims 1-5, wherein:

R^6 is independently 5-membered nitrogen heteroaryl.

13. A compound according to any one of claims 1-12, wherein:

R^6 is independently: 1*H*-imidazol-1-yl, 1*H*-tetrazol-1-yl, 1*H*-tetrazol-3-yl, or 2*H*-tetrazol-5-yl.

14. A compound according to claim 1, wherein the compound is selected from:

(*S*)-3-(1*H*-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-N-(4-methoxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-3-(2*H*-tetrazol-5-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-(trifluoromethoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-(6-methoxypyridin-3-yl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-cyclopropyl-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-(4-hydroxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-4-(4-(difluoromethoxy)phenyl)-3-(1*H*-tetrazol-1-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-3-methyl-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)isoxazole-5-carboxamide,

(*S*)-5-methyl-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide,

N^2-heptyl-N^5-(4-methoxyphenyl)-2-methyl-6-oxo-4-(p-tolyl)-1,2,3,6-tetrahydropyridine-2,5-dicarboxamide,

(*S*)-3-(1*H*-tetrazol-1-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-4-(5,6,7,8-tetrahydronaphthalen-2-yl)-3-(1*H*-tetrazol-5-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,


(*S*)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide,

(*S*)-3-(1*H*-tetrazol-5-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-4-(4-(2,2,2-trifluoroethyl)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one, and

(*S*)-N-(5-methoxypyrazin-2-yl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide;


or a tautomer, or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1, wherein the compound has the following formula:



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 15, wherein the compound has the following formula:



or a tautomer, or a pharmaceutically acceptable salt thereof.

17. A pharmaceutically acceptable salt of the compound according to claim 15 or claim 16.

18. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 17, a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, optionally in combination simultaneously, separately or sequentially with one or more additional therapeutic agents.

19. The pharmaceutical composition according to claim 18, further comprising one or more additional therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents,

anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

20. The pharmaceutical composition according to claim 18, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.


21. A compound of any one of claim 1-17, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, for use in therapy.

22. A compound of any one of claims 1 to 17, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof, for use in preventing, modulating or treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), non-cardiac ischemia, lipid disorders, or glaucoma.

23. A compound for use according to claim 21 or claim 22, wherein the compound is used simultaneously, separately or sequentially with one or more additional therapeutic agents.

What is claimed is:

1. A compound of Formula (I):



(I)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

$\overline{---}$ designates a single or double bond;

x and y can be both a single bond; when x is a double bond, then y is a single bond and R^4 and R^{16} are absent; when y is a double bond, then x is a single bond and R^5 and R^{16} are absent;

R^1 is independently selected from the group consisting of: -CONH(C_{4-18} alkyl), -CONHC_{2-8} haloalkyl, -CONH$(CH_2)_{1-8}$Ph, -CONHCH_2COC_{2-8} alkyl, -$(CH_2)_m$-(C_{3-10} carbocycle substituted with 0-2 R^b and 0-2 R^g), -$(CH_2)_m$-(5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g), and a C_{1-12} hydrocarbon chain substituted with 0-3 R^a; wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated;

R^2 is independently selected from the group consisting of: C_{1-4} alkyl, C_{3-4} cycloalkyl, and C_{1-4} haloalkyl;

R^3 is independently selected from the group consisting of: H, F, Cl, C_{1-4} alkyl and CN;

R^4 and R^5 are independently selected from the group consisting of: H, F, Cl, and C_{1-4} alkyl;

when x is a single bond, R^3 and R^4 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R^6 is independently selected from the group consisting of: H, halo, C_{1-4} alkyl, NO_2, R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, NH_2, $-CONH(C_{1-6}$ alkyl), $-NHCOX_1SO_2R^j$, $-NHCOCH_2PO(OEt)_2$, $-NHCOCOR^j$, $-NHCOCH(OH)R^j$, $-NHCOCH_2COR^j$, $-NHCONHR^j$, and $-OCONR^fR^j$;

X is independently selected from the group consisting of: O, S, NH, CONH, and NHCO;

X_1 is independently C_{1-4} hydrocarbon chain optionally substituted with C_{1-4} alkyl or C_{3-4} cycloalkyl;

when y is a single bond, R^5 and R^6 may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R^{11}, R^{12}, R^{13}, R^{14} and R^{15} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-2 R^i, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $-(CH_2)_m-C_{3-6}$ cycloalkyl, CN, NR^fR^j, OR^j, SR^j, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S;

alternatively, R^{11} and R^{12}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

R^{16} is independently selected from the group consisting of: H and C_{1-4} alkyl;

R^a is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, $N(C_{1-4}$ alkyl$)_2$, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, and $-(CH_2)_n-(CH_2O)_m-(CH_2)_nR^f$;

R^b is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-10} alkyl, C_{1-10} alkoxy, C_{1-10} haloalkyl, C_{1-10} haloalkoxy, C_{1-10} alkylthio, C_{1-10} haloalkylthio, $N(C_{1-4}$ alkyl$)_2$, $-CONH(CH_2)_{4-20}H$, $-O(CH_2)_sO(C_{1-6}$ alkyl), R^c, $-(CH_2)_n-(X)_t-(CH_2)_mR^c$, and $-(CH_2)_n-(CH_2O)_m-(CH_2)_nR^f$;

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, C_{3-6} cycloalkenyl substituted with 0-2 R^d, $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a 5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S; wherein said heterocycle is substituted with 0-2 R^d;

R^d is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, NO_2, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl, OBn and phenyl substituted with 0-2 R^h;

R^e is, at each occurrence, independently selected from the group consisting of: H, C_{1-8} alkyl, C_{1-8} haloalkyl, benzyl optionally substituted with C_{1-4} alkoxy, $CO(C_{1-4}$ alkyl) and COBn;

R^f is, at each occurrence, independently selected from the group consisting of: H and C_{1-4} alkyl;

R^g, R^h and R^i are, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

R^j is, at each occurrence, independently selected from the group consisting of: C_{1-4} alkyl, C_{3-4} cycloalkyl and phenyl;


n, at each occurrence, is independently 0 or 1;

m, at each occurrence, is independently 0, 1, 2, 3, or 4


s, at each occurrence, is independently 1, 2, or 3; and

t, at each occurrence, is independently 0 or 1;

provided that the following compound is excluded:



2. A compound according to claim 1, wherein:

R^1 is independently selected from the group consisting of: -$CONHC_{4-18}$ alkyl, -$CONH(CH_2)_{1-8}$ Ph, C_{1-12} alkyl substituted with 0-2 R^a, C_{1-12} alkenyl substituted with 0-2 R^a, C_{1-12} alkynyl substituted with 0-2 R^a, -$(CH_2)_m$-(phenyl substituted with 0-1 R^b and 0-2 R^g), -$(CH_2)_m$-(C_{3-6} cycloalkyl substituted with 0-1 R^b), and -$(CH_2)_m$-(5- to 6-membered heteroaryl substituted with 0-1 R^b and 0-2 R^g), wherein said heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and .


3. A compound according to claim 2, wherein:

R^{11} and R^{15} are independently selected from the group consisting of: H, C_{1-4} alkyl and halo;

R^{12} and R^{14} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy; and

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 R^i, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, -$(CH_2)_m$-C_{3-4} cycloalkyl, CN, NR^fR^j, SR^j, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), and a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S.


4. A compound according to claim 3, wherein the compound is of Formula (II):



(II)

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 4, wherein:

R^1 is independently selected from the group consisting of: C_{1-6} alkyl, C_{3-6} cycloalkyl, -$CONHC_{4-18}$ alkyl, -$CONHC_{2-8}$ haloalkyl, -$CONH(CH_2)_{1-8}$ Ph, -$(CH_2)_m$-(phenyl substituted with 1 R^b and 0-2 R^g), and a 5- to 6-membered heteroaryl substituted with 0-1 R^b and 0-2 R^g, wherein said heteroaryl is selected from: pyridyl, oxazolyl, thiazolyl and  ;

R^2 is independently selected from the group consisting of: C_{1-4} alkyl and C_{1-4} haloalkyl;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from the group consisting of: NH_2, -$CONH(C_{1-6}$ alkyl), R^c, -$(CH_2)_n$-$(X)_t$-$(CH_2)_m R^c$, -$NHCO(CH_2)SO_2(C_{1-4}$ alkyl), -$NHCOCH_2PO(OEt)_2$, -$NHCOCO(C_{1-4}$ alkyl), -$NHCOCH(OH)(C_{1-4}$ alkyl), -$NHCOCH_2CO(C_{1-4}$ alkyl), -$NHCONH(C_{1-4}$ alkyl), and -$OCONH(C_{1-4}$ alkyl);

R^{11} and R^{15} are independently selected from the group consisting of: H, C_{1-4} alkyl and halo;

R^{12} and R^{14} are independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, -$(CH_2)_m$-C_{3-4} cycloalkyl, CN, $N(C_{1-4}$ alkyl$)_2$, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), pyrazolyl, and morpholinyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising: carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S;

R^b is, at each occurrence, independently selected from the group consisting of: halo, OH, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} haloalkyl, C_{1-10} haloalkoxy, -$O(CH_2)_s O(C_{1-6}$ alkyl),


$N(C_{1-4}$ alkyl$)_2$, -$CONH(CH_2)_{6-20}H$, -$(CH_2)_m(C_{3-6}$ cycloalkyl), -$(CH_2)_m(C_{4-6}$ cycloalkenyl), -$O(CH_2)_m(C_{3-6}$ cycloalkyl), 4-C_{1-4} alkoxy-Ph, -$O(CH_2)_m$Ph, morpholinyl, pyridyl, 2-C_{1-4} alkoxy-pyridin-5-yl, pyrimidinyl, pyrazinyl, and -O-pyrimidinyl;

R^g is, at each occurrence, independently selected from the group consisting of: halo, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

m, at each occurrence, is independently 0, 1, 2 or 3; and

s, at each occurrence, is independently 1, 2, or 3.

6. A compound according to claim 5, wherein:

R^1 is independently selected from the group consisting of: C_{1-6} alkyl, -$CONHC_{4-18}$ alkyl, -$CONH(CH_2)_{1-8}$Ph, and 

;

R^6 is independently selected from the group consisting of: NH_2, -$CONH(C_{1-6}$ alkyl), -$NHCOCH_2PO(OEt)_2$, -$NHCO(CH_2)SO_2(C_{1-4}$ alkyl), R^c, OR^c, -$CONHR^c$, and -$NHCOR^c$;

R^{12} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, -$(CH_2)_m$-C_{3-4} cycloalkyl, CN, $N(C_{1-4}$ alkyl$)_2$, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), pyrazolyl, and morpholinyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;


R^{14} is independently selected from the group consisting of: H and C_{1-4} alkoxy;

R^b is, at each occurrence, independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-10} haloalkoxy, -$O(CH_2)_sO(C_{1-6}$ alkyl), -$CONH(CH_2)_{6-20}H$, -$(CH_2)_m(C_{3-6}$ cycloalkyl), -$(CH_2)_m(C_{4-6}$ cycloalkenyl),

-O$(CH_2)_m$(C_{3-6} cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C_{1-4} alkoxy-pyridin-5-yl, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidinyl; and

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, -$(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d.

7. A compound according to claim 6, wherein:

R^1 is 

;

R^6 is independently selected from the group consisting of: NH_2, -CONH(C_{1-4} alkyl), OPh, -CONH(C_{3-6} cycloalkyl), -CONHPh, -CONH-(2-halo-Ph), -CONH-(3-halo-Ph), -CONH-(4-halo-Ph), -CONH-(4-C_{1-4} alkyl-Ph), -CONH(4-OH-Ph), -CONH-(3-C_{1-4} alkoxy-Ph), -CONH-(4-C_{1-4} alkoxy-Ph), -CONH-(4-C_{1-4} haloalkyl-Ph), -CONH-(4-C_{1-4} haloalkoxy-Ph), -CONH-(4-CN-Ph), -CONH-(4-tetrazolyl-Ph), -CONH-(3-halo-4-C_{1-4} alkyl-Ph), -CONH-(3-halo-4-C_{1-4} alkoxy-Ph), -CONH$(CH_2)_2$Ph, -CONH(4-(4-C_{1-4} alkoxy-Ph)-thiazol-2-yl), -CONH(1-C_{1-4} alkyl-pyrazol-3-yl), -CONH(5-C_{1-4} alkoxy-pyrid-2-yl), -CONH(6-C_{1-4} alkoxy-pyrid-3-yl), -CONH(5-C_{1-4} alkoxy-pyrazin-2-yl), -CONH(6-C_{1-4} alkoxy-pyridazin-3-yl), -NHCO$(CH_2)SO_2$(C_{1-4} alkyl), -NHCOPh, -NHCO(2-C_{1-4} alkyl-Ph), -NHCO(3-C_{1-4} alkyl-Ph), -NHCO(4-C_{1-4} alkyl-Ph), -NHCO(2-halo-Ph), -NHCO(3-halo-Ph), -NHCO(2-C_{1-4} haloalkyl-Ph), -NHCO(2-C_{1-4} haloalkoxy-Ph), -NHCO(2-halo-4-halo-Ph), -NHCO(2-halo-5-halo-Ph), -NHCO(oxazolyl), -NHCO(isoxazolyl), -NHCO(3-C_{1-4} alkyl-isoxazol-5-yl), -NHCO(4-C_{1-4} alkyl-isoxazol-5-yl), -NHCO(3-C_{1-4} alkoxy-isoxazol-5-yl), -NHCO(4-C_{1-4} alkoxy-isoxazol-5-yl), -NHCO(3-halo-isoxazol-5-yl), -NHCO(3-OBn-isoxazol-5-yl), -NHCO(3-(2-halo-Ph)-isoxazol-5-yl), -NHCO(3-(3-halo-Ph)-isoxazol-5-yl),

-NHCO(5-C_{1-4} alkyl-1*H*-pyrazol-3-yl), imidazolyl, -NHCO(5-C_{1-4} alkyl-1,3,4-oxadiazol-2-yl), -NHCO(1-C_{1-4} alkyl-1,2,3-triazol-4-yl), -NHCO(6-C_{1-4} alkoxy-pyrid-3-yl), -NHCO(pyrazinyl), -NHCO(6-halo-pyridazin-3-yl), 5-C_{1-4} haloalkyl-1,3,4-oxadiazol-2-yl, 3-NO_2-1*H*-1,2,4-triazol-1-yl, tetrazolyl and 5-C_{1-4} alkyl-tetrazol-1-yl;

R^b is independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-8} haloalkoxy, -CONH$(CH_2)_{6-20}$H, C_{3-6} cycloalkyl, C_{4-6} cycloalkenyl, -O$(CH_2)_m$(C_{3-6} cycloalkyl), phenoxy, benzoxy, pyrimidinyl, pyrazinyl and -O-pyrimidinyl; and

R^g is independently selected from the group consisting of: halo and C_{1-4} alkyl.

8. A compound according to claim 7, wherein:

R^2 is independently selected from the group consisting of: CF_3 and Me;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from the group consisting of: NH_2, -CONHMe, OPh, -CONH(cyclopropyl), -CONH(cyclobutyl), -CONH(cyclopentyl), -CONH(cyclohexyl), -CONHPh, -CONH(4-F-Ph), -CONH(2-Cl-Ph), -CONH(4-Cl-Ph), -CONH(4-Me-Ph), -CONH(4-OH-Ph), -CONH(3-OMe-Ph), -CONH(4-OMe-Ph), -CONH(4-CF_3-Ph), -CONH(4-OCF_3-Ph), -CONH(1-Me-pyrazol-3-yl), -CONH(4-(1*H*-tetrazol-2-yl)-Ph), -CONH(4-(2*H*-tetrazol-5-yl)-Ph), -CONH(3-F-4-Me-Ph), -CONH(3-F-4-OMe-Ph), -CONH$(CH_2)_2$Ph, -CONH(5-OMe-pyrid-2-yl), -CONH(6-OMe-pyrid-3-yl), -CONH(5-OMe-pyrazin-2-yl), -CONH(6-OMe-pyridazin-3-yl), -NHCO$(CH_2)SO_2$Me, -NHCOPh, -NHCO(2-Me-Ph), -NHCO(3-Me-Ph), -NHCO(4-Me-Ph), -NHCO(2-Cl-Ph), -NHCO(3-Cl-Ph), -NHCO(2-Cl-4-F-Ph), -NHCO(2-Cl-5-F-Ph), -NHCO(isoxazol-5-yl), -NHCO(3-Me-isoxazol-5-yl), -NHCO(4-Me-isoxazol-5-yl), -NHCO(3-OMe-isoxazol-5-yl), -NHCO(3-Br-isoxazol-5-yl), -NHCO(3-(2-Cl-Ph)-isoxazol-5-yl), -NHCO(3-(3-F-Ph)-isoxazol-5-yl), -NHCO(3-OBn-isoxazol-5-yl), 1*H*-imidazol-1-yl, -NHCO(5-Me-1,3,4-oxadiazol-2-yl), -NHCO(1-Me-1,2,3-triazol-4-yl),

-NHCO(6-OMe-pyrid-3-yl), -NHCO(6-Cl-pyridazin-3-yl), 5-CF_3-1,3,4-oxadiazol-2-yl, 1*H*-tetrazol-1-yl, 1*H*-tetrazol-3-yl, and 2*H*-tetrazol-5-yl;

R^{11} and R^{15} are independently selected from the group consisting of: H, Me, F, and Cl;

R^{12} is independently selected from the group consisting of: H, F, Cl, Me and OMe;

R^{13} is independently selected from the group consisting of: H, F, Cl, Br, Me, OMe, OEt, CH_2OMe, CF_3, CH_2CF_3, $OCHF_2$, OCF_3, CN, $N(Me)_2$, cyclopropyl and cyclopropylmethyl;


alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is H;

R^b is, at each occurrence, independently selected from the group consisting of: n-pentyl, methoxy, n-butoxy, i-butoxy, i-pentoxy, -$O(CH_2)_{1-6}CF_3$, -$O(CH_2)_{1-4}CF_2CF_3$, -$CONH(CH_2)_{6-20}H$, cyclopropyl, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, -$O(CH_2)_2$(cyclopentyl), phenoxy, benzoxy, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidin-2-yl; and

R^g is F.

9. A compound according to claim 5, wherein:

R^1 is 

;

R^2 is independently selected from CF_3 and CH_3;

R^6 is independently selected from: R^c, -$CONHR^c$, -$NHCOR^c$, and -$NHCOCH_2SO_2$(C_{1-4} alkyl);

R^b is independently selected from: -$O(CH_2)_{1-6}CF_3$, -$O(CH_2)_{1-4}CF_2CF_3$, -$CONH(CH_2)_{6-20}H$, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, -$O(CH_2)_2$(cyclopentyl), phenoxy, benzoxy, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidin-2-yl;

R^c is, at each occurrence, independently selected from the group consisting of: $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d; and

R^d is, at each occurrence, independently selected from the group consisting of: halo, OH, CN, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl and OBn.

10. A compound according to claim 1, wherein the compound is selected from:

(*S*)-3-(1*H*-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-N-(4-methoxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-3-(2*H*-tetrazol-5-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-(trifluoromethoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-(6-methoxypyridin-3-yl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-cyclopropyl-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-N-(4-hydroxyphenyl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(*S*)-4-(4-(difluoromethoxy)phenyl)-3-(1*H*-tetrazol-1-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-3-methyl-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)isoxazole-5-carboxamide,

(*S*)-5-methyl-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)-1,3,4-oxadiazole-2-carboxamide,

N^2-heptyl-N^5-(4-methoxyphenyl)-2-methyl-6-oxo-4-(p-tolyl)-1,2,3,6-tetrahydropyridine-2,5-dicarboxamide,

(*S*)-3-(1*H*-tetrazol-1-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-4-(5,6,7,8-tetrahydronaphthalen-2-yl)-3-(1*H*-tetrazol-5-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one,

(*S*)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide,

(*S*)-3-(1*H*-tetrazol-5-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-4-(4-(2,2,2-trifluoroethyl)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1*H*)-one, and

(*S*)-N-(5-methoxypyrazin-2-yl)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide;

or a tautomer, or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 1, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 9, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 10, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition according to claim 11, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic


agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

15. The pharmaceutical composition according to claim 11, further comprising a dipeptidyl peptidase-IV inhibitor.

16. The pharmaceutical composition according to claim 11, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

17. The pharmaceutical composition according to claim 11, further comprising a sodium-glucose transporter-2 inhibitor.

18. A compound according to claim 5, wherein:

R^1 is independently selected from the group consisting of: C_{1-6} alkyl, $-CONHC_{4-18}$ alkyl, 

$-CONH(CH_2)_{1-8}Ph$, and ;

R^6 is independently selected from the group consisting of: NH_2, $-CONH(C_{1-6}$ alkyl), $-NHCOCH_2PO(OEt)_2$, $-NHCO(CH_2)SO_2(C_{1-4}$ alkyl), R^c, OR^c, $-CONHR^c$, and $-NHCOR^c$;

R^{12} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, $-(CH_2)_m$-C_{3-4} cycloalkyl, CN, $N(C_{1-4}$ alkyl$)_2$, $NHCO_2(C_{1-4}$ alkyl), $NHSO_2(C_{1-4}$ alkyl), pyrazolyl, and morpholinyl;


alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is independently selected from the group consisting of: H and C_{1-4} alkoxy;

R^b is, at each occurrence, independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-10} haloalkoxy, $-O(CH_2)_sO(C_{1-6}$ alkyl), $-CONH(CH_2)_{6-20}H$, $-(CH_2)_m(C_{3-6}$ cycloalkyl), $-(CH_2)_m(C_{4-6}$ cycloalkenyl), $-O(CH_2)_m(C_{3-6}$ cycloalkyl), phenoxy, benzoxy, morpholinyl, 2-C_{1-4} alkoxy-pyridin-5-yl, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidinyl; and

R^c is, at each occurrence, independently selected from the group consisting of: C_{3-6} cycloalkyl substituted with 0-2 R^d, $-(CH_2)_m$-(phenyl substituted with 0-3 R^d), and a heteroaryl selected from: oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, triazolyl, tetrazolyl, pyridyl, and pyrazinyl; wherein said heteroaryl is substituted with 0-2 R^d.

19. A compound according to claim 18, wherein:

R^1 is 

;

R^6 is independently selected from the group consisting of: NH_2, $-CONH(C_{1-4}$ alkyl), OPh, $-CONH(C_{3-6}$ cycloalkyl), -CONHPh, -CONH-(2-halo-Ph), -CONH-(3-halo-Ph), -CONH-(4-halo-Ph), -CONH-(4-C_{1-4} alkyl-Ph), -CONH(4-OH-Ph), -CONH-(3-C_{1-4} alkoxy-Ph), -CONH-(4-C_{1-4} alkoxy-Ph), -CONH-(4-C_{1-4} haloalkyl-Ph), -CONH-(4-C_{1-4} haloalkoxy-Ph), -CONH-(4-CN-Ph), -CONH-(4-tetrazolyl-Ph), -CONH-(3-halo-4-C_{1-4} alkyl-Ph), -CONH-(3-halo-4-C_{1-4} alkoxy-Ph), $-CONH(CH_2)_2Ph$,

-CONH(4-(4-C_{1-4} alkoxy-Ph)-thiazol-2-yl), -CONH(1-C_{1-4} alkyl-pyrazol-3-yl), -CONH(5-C_{1-4} alkoxy-pyrid-2-yl), -CONH(6-C_{1-4} alkoxy-pyrid-3-yl), -CONH(5-C_{1-4} alkoxy-pyrazin-2-yl), -CONH(6-C_{1-4} alkoxy-pyridazin-3-yl), -NHCO(CH_2)SO_2(C_{1-4} alkyl), -NHCOPh, -NHCO(2-C_{1-4} alkyl-Ph), -NHCO(3-C_{1-4} alkyl-Ph), -NHCO(4-C_{1-4} alkyl-Ph), -NHCO(2-halo-Ph), -NHCO(3-halo-Ph), -NHCO(2-C_{1-4} haloalkyl-Ph), -NHCO(2-C_{1-4} haloalkoxy-Ph), -NHCO(2-halo-4-halo-Ph), -NHCO(2-halo-5-halo-Ph), -NHCO(oxazolyl), -NHCO(isoxazolyl), -NHCO(3-C_{1-4} alkyl-isoxazol-5-yl), -NHCO(4-C_{1-4} alkyl-isoxazol-5-yl), -NHCO(3-C_{1-4} alkoxy-isoxazol-5-yl), -NHCO(4-C_{1-4} alkoxy-isoxazol-5-yl), -NHCO(3-halo-isoxazol-5-yl), -NHCO(3-OBn-isoxazol-5-yl), -NHCO(3-(2-halo-Ph)-isoxazol-5-yl), -NHCO(3-(3-halo-Ph)-isoxazol-5-yl), -NHCO(5-C_{1-4} alkyl-1*H*-pyrazol-3-yl), imidazolyl, -NHCO(5-C_{1-4} alkyl-1,3,4-oxadiazol-2-yl), -NHCO(1-C_{1-4} alkyl-1,2,3-triazol-4-yl), -NHCO(6-C_{1-4} alkoxy-pyrid-3-yl), -NHCO(pyrazinyl), -NHCO(6-halo-pyridazin-3-yl), 5-C_{1-4} haloalkyl-1,3,4-oxadiazol-2-yl, 3-NO_2-1*H*-1,2,4-triazol-1-yl, tetrazolyl and 5-C_{1-4} alkyl-tetrazol-1-yl;

R^b is independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-8} haloalkoxy, -CONH(CH_2)$_{6-20}$H, C_{3-6} cycloalkyl, C_{4-6} cycloalkenyl, -O(CH_2)$_m$(C_{3-6} cycloalkyl), phenoxy, benzoxy, pyrimidinyl, pyrazinyl and -O-pyrimidinyl; and

R^g is independently selected from the group consisting of: halo and C_{1-4} alkyl.

20. A compound according to claim 19, wherein:

R^2 is independently selected from the group consisting of: CF_3 and Me;

R^3 is independently selected from the group consisting of: H and F;

R^4 is independently selected from the group consisting of: H and F;

R^6 is independently selected from the group consisting of: NH_2, -CONHMe, OPh, -CONH(cyclopropyl), -CONH(cyclobutyl), -CONH(cyclopentyl), -CONH(cyclohexyl), -CONHPh, -CONH(4-F-Ph), -CONH(2-Cl-Ph), -CONH(4-Cl-Ph), -CONH(4-Me-Ph),

-CONH(4-OH-Ph), -CONH(3-OMe-Ph), -CONH(4-OMe-Ph), -CONH(4-CF_3-Ph), -CONH(4-OCF_3-Ph), -CONH(1-Me-pyrazol-3-yl), -CONH(4-(1*H*-tetrazol-2-yl)-Ph), -CONH(4-(2*H*-tetrazol-5-yl)-Ph), -CONH(3-F-4-Me-Ph), -CONH(3-F-4-OMe-Ph), -CONH$(CH_2)_2$Ph, -CONH(5-OMe-pyrid-2-yl), -CONH(6-OMe-pyrid-3-yl), -CONH(5-OMe-pyrazin-2-yl), -CONH(6-OMe-pyridazin-3-yl), -NHCO$(CH_2)SO_2$Me, -NHCOPh, -NHCO(2-Me-Ph), -NHCO(3-Me-Ph), -NHCO(4-Me-Ph), -NHCO(2-Cl-Ph), -NHCO(3-Cl-Ph), -NHCO(2-Cl-4-F-Ph), -NHCO(2-Cl-5-F-Ph), -NHCO(isoxazol-5-yl), -NHCO(3-Me-isoxazol-5-yl), -NHCO(4-Me-isoxazol-5-yl), -NHCO(3-OMe-isoxazol-5-yl), -NHCO(3-Br-isoxazol-5-yl), -NHCO(3-(2-Cl-Ph)-isoxazol-5-yl), -NHCO(3-(3-F-Ph)-isoxazol-5-yl), -NHCO(3-OBn-isoxazol-5-yl), 1*H*-imidazol-1-yl, -NHCO(5-Me-1,3,4-oxadiazol-2-yl), -NHCO(1-Me-1,2,3-triazol-4-yl), -NHCO(6-OMe-pyrid-3-yl), -NHCO(6-Cl-pyridazin-3-yl), 5-CF_3-1,3,4-oxadiazol-2-yl, 1*H*-tetrazol-1-yl, 1*H*-tetrazol-3-yl, and 2*H*-tetrazol-5-yl;

R^{11} and R^{15} are independently selected from the group consisting of: H, Me, F, and Cl;

R^{12} is independently selected from the group consisting of: H, F, Cl, Me and OMe;

R^{13} is independently selected from the group consisting of: H, F, Cl, Br, Me, OMe, OEt, CH_2OMe, CF_3, CH_2CF_3, $OCHF_2$, OCF_3, CN, $N(Me)_2$, cyclopropyl and cyclopropylmethyl;

alternatively, R^{12} and R^{13}, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered saturated heterocyclic ring comprising: carbon atoms and 1-2 oxygen atoms;

R^{14} is H;

R^b is, at each occurrence, independently selected from the group consisting of: n-pentyl, methoxy, n-butoxy, i-butoxy, i-pentoxy, -O$(CH_2)_{1-6}CF_3$, -O$(CH_2)_{1-4}CF_2CF_3$, -CONH$(CH_2)_{6-20}$H, cyclopropyl, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, -O$(CH_2)_2$(cyclopentyl), phenoxy, benzoxy, pyrimidin-5-yl, pyrazin-2-yl and -O-pyrimidin-2-yl; and

R^g is F.

21. A compound according to claim 9, wherein:

R^{13} is independently selected from the group consisting of: H, halo, C_{1-4} alkyl substituted with 0-1 C_{1-4} alkoxy, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, CN or C_{3-4} cycloalkyl.

22. A compound according to claim 20, wherein:

R^1 is independently 

23. A compound according to claim 22, wherein:

R^b is independently selected from: $-O(CH_2)_{1-6}CF_3$, and $-O(CH_2)_{1-4}CF_2CF_3$.

24. A compound according to claim 23, wherein:

R^6 is independently 5-membered nitrogen heteroaryl.

25. A compound according to claim 24, wherein:

R^6 is independently: 1*H*-imidazol-1-yl, 1*H*-tetrazol-1-yl, 1*H*-tetrazol-3-yl, or 2*H*-tetrazol-5-yl.

26. A compound according to claim 1, wherein the compound is selected from:

(S)-3-(1H-tetrazol-5-yl)-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,

(S)-3-(2H-tetrazol-5-yl)-4-(p-tolyl)-6-(4-((6,6,6-trifluorohexyl)oxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one,


(S)-2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-N-(4-(trifluoromethoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridine-3-carboxamide,

(S)-4-(4-(difluoromethoxy)phenyl)-3-(1H-tetrazol-1-yl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-5,6-dihydropyridin-2(1H)-one, and

(S)-2-(methylsulfonyl)-N-(2-oxo-4-(p-tolyl)-6-(4-(4,4,4-trifluorobutoxy)phenyl)-6-(trifluoromethyl)-1,2,5,6-tetrahydropyridin-3-yl)acetamide;


or a tautomer, or a pharmaceutically acceptable salt thereof.

27. A racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof.

28. A compound having the following formula:




or a tautomer, or a pharmaceutically acceptable salt thereof.

29. A compound according to claim 28, wherein the compound has the following formula:




30. A compound according to claim 1, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof.

31. A compound according to claim 30, wherein the compound has the following formula:




or a tautomer, or a pharmaceutically acceptable salt thereof.

32. A compound according to claim 31, wherein the compound has the following formula:




33. A compound according to claim 1, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof.

34. A compound according to claim 33, wherein the compound has the following formula:




or a tautomer, or a pharmaceutically acceptable salt thereof.

35. A compound according to claim 34, wherein the compound has the following formula:




36. A compound according to claim 1, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof.

37. A compound according to claim 36, wherein the compound has the following formula:




or a tautomer, or a pharmaceutically acceptable salt thereof.

38. A compound according to claim 37, wherein the compound has the following formula:




39. A compound according to claim 1, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof.

40. A compound according to claim 39, wherein the compound has the following formula:



or a tautomer, or a pharmaceutically acceptable salt thereof.

41. A compound according to claim 40, wherein the compound has the following formula:



42. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 18, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

43. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 25, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

44. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 26.

45. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 27.

46. The pharmaceutical composition according to claim 45, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents,

anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

47. The pharmaceutical composition according to claim 45, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

48. The pharmaceutical composition according to claim 45, further comprising a dipeptidyl peptidase-IV inhibitor.

49. The pharmaceutical composition according to claim 45, further comprising a sodium-glucose transporter-2 inhibitor.

50. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 28.

51. The pharmaceutical composition according to claim 50, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

52. The pharmaceutical composition according to claim 50, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

53. The pharmaceutical composition according to claim 50, further comprising a dipeptidyl peptidase-IV inhibitor.

54. The pharmaceutical composition according to claim 51, further comprising a sodium-glucose transporter-2 inhibitor.

55. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 29.


56. The pharmaceutical composition according to claim 55, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

57. The pharmaceutical composition according to claim 55, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

58. The pharmaceutical composition according to claim 55, further comprising a dipeptidyl peptidase-IV inhibitor.


59. The pharmaceutical composition according to claim 55, further comprising a sodium-glucose transporter-2 inhibitor.

60. A compound according to claim 27, where the compound is a racemic mixture of the compound having the following formula:



and its enantiomer, or a pharmaceutically acceptable salt thereof.

61. A compound according to claim 28, where the compound has the following formula:



or a pharmaceutically acceptable salt thereof.

62. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 60.

63. The pharmaceutical composition according to claim 60, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

64. The pharmaceutical composition according to claim 60, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

65. The pharmaceutical composition according to claim 60, further comprising a dipeptidyl peptidase-IV inhibitor.

66. The pharmaceutical composition according to claim 63, further comprising a sodium-glucose transporter-2 inhibitor.

67. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 61.

68. The pharmaceutical composition according to claim 67, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic


agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

69. The pharmaceutical composition according to claim 67, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.


70. The pharmaceutical composition according to claim 67, further comprising a dipeptidyl peptidase-IV inhibitor.

71. The pharmaceutical composition according to claim 67, further comprising a sodium-glucose transporter-2 inhibitor.


72. A compound selected from:




,




,




,




,




,




,



,



, and



,

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

73. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 72.


74. The pharmaceutical composition according to claim 73, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

75. The pharmaceutical composition according to claim 73, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

76. The pharmaceutical composition according to claim 73, further comprising a dipeptidyl peptidase-IV inhibitor.

77. The pharmaceutical composition according to claim 73, further comprising a sodium-glucose transporter-2 inhibitor.

78. A compound has the following formula:



or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

79. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 78.

80. The pharmaceutical composition according to claim 79, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity


agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

81. The pharmaceutical composition according to claim 79, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

82. The pharmaceutical composition according to claim 79, further comprising a dipeptidyl peptidase-IV inhibitor.

83. The pharmaceutical composition according to claim 79, further comprising a sodium-glucose transporter-2 inhibitor.

84. A compound according to claim 78, wherein the compound has the following formula:



85. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of claim 84.

86. The pharmaceutical composition according to claim 85, further comprising one or more other suitable therapeutic agents selected from: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-restenotic agents, lipid lowering agents, anorectic agents, and appetite suppressants.

87. The pharmaceutical composition according to claim 85, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

88. The pharmaceutical composition according to claim 85, further comprising a dipeptidyl peptidase-IV inhibitor.

89. The pharmaceutical composition according to claim 85, further comprising a sodium-glucose transporter-2 inhibitor.